Skip to main content
AmigoFish

Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC

From BiotechTV - News · · 11 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.

Back to BiotechTV - News · Report a problem